Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced ...
Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following ...
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stroma-rich tumoursUS trial (OCTOPOD-IP ...
Huntsman Cancer Institute at the University of Utah stands at the forefront of innovative cancer research and treatment. Phase 1 clinical trials are key to finding better ways to treat cancer safely ...
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at ...
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM). This is an ASCO Meeting ...
Fred Hutchinson Cancer Center leads the way when it comes to offering eligible patients alternative options when conventional therapies no longer work. With more than two dozen phase 1 clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results